Bedel Financial Consulting’s Opus Genetics IRD Stock Holding History

Bedel Financial Consulting’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,000	Closed	-$68.2K	–	321
2026 Q1	$68.2K	Hold	15,000	–	–	0.01%	294
2025 Q4	$30.2K	Hold	15,000	–	–	﹤0.01%	289
2025 Q3	$24.8K	Hold	15,000	–	–	﹤0.01%	284
2025 Q2	$14.1K	Hold	15,000	–	–	﹤0.01%	273
2025 Q1	$14K	Hold	15,000	–	–	﹤0.01%	260
2024 Q4	$18.2K	Hold	15,000	–	–	﹤0.01%	266
2024 Q3	$19.6K	Hold	15,000	–	–	﹤0.01%	259
2024 Q2	$23K	Hold	15,000	–	–	﹤0.01%	250
2024 Q1	$30.2K	Hold	15,000	–	–	﹤0.01%	253
2023 Q4	$45.2K	Hold	15,000	–	–	0.01%	242
2023 Q3	$50.2K	Hold	15,000	–	–	0.01%	232
2023 Q2	$65.1K	Hold	15,000	–	–	0.01%	237
2023 Q1	$56.2K	Hold	15,000	–	–	0.01%	225
2022 Q4	$53K	Hold	15,000	–	–	0.01%	226
2022 Q3	$31K	Buy	+15,000	New	+$32.4K	0.01%	212

Other funds holding IRD

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bedel Financial Consulting's IRD Position: Q2 2026 in Review

Bedel Financial Consulting sold out of Opus Genetics (IRD) in Q2 2026, closing a stake of 15,000 shares — an estimated $68.2K sold.

Bedel Financial Consulting first reported a position in IRD in Q3 2022 and held it in 15 quarters. The position peaked at $68.2K in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

Bedel Financial Consulting reported no remaining Opus Genetics position as of Q2 2026 after selling out during the quarter.
Bedel Financial Consulting sold 15,000 Opus Genetics shares in Q2 2026, an estimated $68.2K.
Bedel Financial Consulting first reported a position in Opus Genetics in Q3 2022 and held it in 15 quarters.
Bedel Financial Consulting's Opus Genetics position peaked at $68.2K in Q1 2026.
103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Bedel Financial Consulting's 13F filing for Q2 2026, filed 29 Jul 2026.